Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma

Patients treated with dabrafenib/trametinib (DAB/TRA) exhibit a large interindividual variability in clinical outcomes. The aims of this study were to characterize the pharmacokinetics of DAB, hydroxy-dabrafenib (OHD), and TRA in BRAF-mutated patients and to investigate the exposure–response relatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Balakirouchenane, David, Guégan, Sarah, Csajka, Chantal, Jouinot, Anne, Heidelberger, Valentine, Puszkiel, Alicja, Zehou, Ouidad, Khoudour, Nihel, Courlet, Perrine, Kramkimel, Nora, Lheure, Coralie, Franck, Nathalie, Huillard, Olivier, Arrondeau, Jennifer, Vidal, Michel, Goldwasser, Francois, Maubec, Eve, Dupin, Nicolas, Aractingi, Selim, Guidi, Monia, Blanchet, Benoit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226106/
https://www.ncbi.nlm.nih.gov/pubmed/32283865
http://dx.doi.org/10.3390/cancers12040931

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226106/
https://www.ncbi.nlm.nih.gov/pubmed/32283865
http://dx.doi.org/10.3390/cancers12040931

Ejemplares similares